| Literature DB >> 21094856 |
X-J Zhang1, Y-D Kang, L Xiao, R-D Li, G-S Ding, Z-X Wang, Z-R Fu.
Abstract
Tacrolimus (Tac, FK506) is a widely used T-cell-targeted immunosuppression drug known as a calcineurin inhibitor. However, its pharmacologic effects on T-helper type 17 (Th17) cells have not been fully elucidated. Herein, we demonstrate that Tac inhibits Th17 cell differentiation and proliferation, and expression of IL-17 messenger RNA. The proposed mechanism is that Tac inhibits calcineurin and T-cell receptor stimulation-induced cell division. Because Th17 cells participate in allograft rejection, the results of the present study suggest a novel model of immunosuppression effects of Tac. In addition, they provide further implications for the therapeutic immunosuppression effects of Tac on allograft rejection.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21094856 DOI: 10.1016/j.transproceed.2010.08.033
Source DB: PubMed Journal: Transplant Proc ISSN: 0041-1345 Impact factor: 1.066